-- ============================================================================
-- SURGERY 3 MCQ BATCH 43: Vascular Surgery (Questions 2521-2580)
-- Topic: AAA, Peripheral Arterial Disease, Carotid Disease, Venous Disease
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Abdominal Aortic Aneurysm (1-15)
('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'An abdominal aortic aneurysm (AAA) is defined as aortic diameter of:',
'Greater than 2 cm', 'Greater than 3 cm (or more than 50% increase from normal diameter)', 'Greater than 5 cm', 'Greater than 1 cm', 'Any enlargement',
'B', 'AAA definition: aortic diameter greater than 3 cm (normal infrarenal aorta approximately 2 cm in adults) or greater than 50% increase from expected normal diameter. True aneurysm: involves all three vessel wall layers (intima, media, adventitia). Location: infrarenal (most common - 90%), suprarenal, thoracoabdominal. Risk factors: smoking (strongest), male, age, family history, hypertension, atherosclerosis, connective tissue disorders. Reference: Chaikof EL. J Vasc Surg. 2018 (SVS Guidelines).',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The most significant risk factor for AAA development and rupture is:',
'Diabetes', 'Smoking (also the most modifiable)', 'Exercise', 'Obesity', 'Low cholesterol',
'B', 'Smoking and AAA: strongest risk factor for development (5-8x increased risk), progression, and rupture. Mechanism: inflammation, proteolytic enzyme activation (MMPs), impaired collagen synthesis. Other risk factors: male sex, age greater than 65, family history, hypertension, hyperlipidemia, peripheral vascular disease. Interestingly, diabetes is protective against AAA development (unclear mechanism - possibly related to glycation of matrix proteins). Reference: Lederle FA. JAMA. 2002.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Screening for AAA is recommended for:',
'All adults', 'Men aged 65-75 who have ever smoked (one-time ultrasound)', 'Only symptomatic patients', 'Women over 80', 'Children',
'B', 'AAA screening (USPSTF): one-time ultrasound for men aged 65-75 who have ever smoked. Benefit: reduces AAA-related mortality. Not recommended: women (lower prevalence, less benefit). Consider selective screening: men 65-75 who never smoked, women 65-75 who smoked with family history. Ultrasound: highly accurate (sensitivity nearly 100%), noninvasive, low cost. Reference: USPSTF. Ann Intern Med. 2019.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The threshold diameter for elective AAA repair is typically:',
'3 cm', '5.5 cm for men, 5.0 cm for women, or rapid expansion greater than 1 cm per year', '4 cm', '7 cm', '2 cm',
'B', 'AAA repair thresholds: (1) Diameter: 5.5 cm men, 5.0 cm women (higher rupture risk relative to size in women). (2) Rapid expansion: greater than 1 cm/year or greater than 0.5 cm in 6 months. (3) Symptomatic aneurysm at any size. Below threshold: surveillance ultrasound (3-3.5 cm: every 3 years, 3.5-4.4 cm: annually, 4.5-5.4 cm: every 6 months). Small aneurysm trials: no benefit to early repair. Rupture risk increases exponentially with size. Reference: Chaikof EL. J Vasc Surg. 2018.',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The classic triad of ruptured AAA is:',
'Fever, jaundice, RUQ pain', 'Sudden severe abdominal or back pain, hypotension, and pulsatile abdominal mass', 'Nausea, vomiting, diarrhea', 'Chest pain, dyspnea, syncope', 'Flank pain, hematuria, fever',
'B', 'Ruptured AAA triad: (1) Sudden severe abdominal or back pain (tearing quality), (2) Hypotension/shock, (3) Pulsatile abdominal mass. Note: complete triad present in only 25-50%. Contained rupture: hemodynamically stable initially (retroperitoneal containment). Free rupture: rapid exsanguination. Misdiagnosis common: renal colic, diverticulitis, MI. High index of suspicion needed. Mortality: 80-90% overall, 40-50% even with emergent repair. Reference: Reimerink JJ. Br J Surg. 2013.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'EVAR (endovascular aneurysm repair) compared to open surgical repair:',
'Has higher perioperative mortality', 'Has lower perioperative mortality but requires suitable anatomy and long-term surveillance', 'Is always preferred', 'Has no complications', 'Lasts longer without reintervention',
'B', 'EVAR vs open repair: EVAR advantages: lower perioperative mortality (1-2% vs 4-5%), shorter hospital stay, faster recovery. EVAR disadvantages: requires suitable anatomy (adequate neck, iliac access), higher reintervention rate, requires lifelong surveillance for endoleaks, graft migration. Long-term survival: similar or slightly worse with EVAR (reinterventions, ruptures). Open repair: more durable, no surveillance needed after healing. Patient selection crucial. Reference: Greenhalgh RM. Lancet. 2004 (EVAR-1 trial).',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Type II endoleak following EVAR is:',
'Leak at proximal attachment site', 'Retrograde flow into aneurysm sac from branch vessels (lumbar arteries, IMA)', 'Leak at distal attachment', 'Graft material defect', 'No identifiable source',
'B', 'EVAR endoleaks classification: Type I: attachment site leak (proximal Ia, distal Ib) - requires treatment. Type II: retrograde flow from branch vessels (lumbar, IMA) - most common, often benign, treat if sac expanding. Type III: graft defect or modular disconnection - requires treatment. Type IV: graft porosity (early) - self-limiting. Type V (endotension): sac expansion without visible leak. Treatment: Type I and III require urgent repair, Type II observed unless sac growth. Reference: White GH. J Endovasc Surg. 1997.',
'medium', 'knowledge'),

-- Peripheral Arterial Disease (16-35)
('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Intermittent claudication is characterized by:',
'Pain at rest', 'Reproducible muscular pain brought on by walking and relieved by rest, caused by arterial insufficiency', 'Sudden onset paralysis', 'Swelling', 'Numbness only at night',
'B', 'Intermittent claudication: (1) Muscular pain (calf most common - SFA disease, thigh/buttock - aortoiliac), (2) Reproducible with same walking distance, (3) Relieved by standing still (2-5 minutes), (4) Not positional (unlike spinal stenosis which needs bending/sitting). Cause: fixed arterial stenosis limiting exercise-induced increased oxygen demand. Natural history: most stable or improve with exercise, 1-2%/year progress to CLI. Treatment: risk factor modification, exercise therapy, cilostazol. Reference: Criqui MH. Circulation. 2015.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The ankle-brachial index (ABI) for peripheral arterial disease is interpreted as:',
'Only ankle pressure', 'Ratio of ankle to arm systolic pressure: ABI less than 0.9 is abnormal and diagnostic of PAD', 'Only arm pressure', 'Diastolic pressures', 'Mean arterial pressure',
'B', 'Ankle-brachial index: ratio of highest ankle (dorsalis pedis or posterior tibial) to highest brachial systolic pressure. Interpretation: greater than 1.3: non-compressible (calcified - diabetes), 1.0-1.3: normal, 0.91-0.99: borderline, less than 0.9: PAD (90% sensitive, 95% specific), less than 0.4: severe PAD/critical limb ischemia. Limitations: calcified vessels give falsely elevated ABI. Alternatives: toe-brachial index (TBI), pulse volume recordings. Reference: Aboyans V. Eur Heart J. 2018.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The most common site of atherosclerotic occlusion in lower extremity PAD is:',
'Aorta', 'Superficial femoral artery (especially at the adductor canal/Hunter canal)', 'Common iliac artery', 'Popliteal artery', 'Tibial arteries',
'B', 'SFA: most commonly affected artery in PAD. Location: adductor canal (Hunter canal) - narrowest point, mechanical stress. Pattern: infrainguinal disease most common overall. Aortoiliac disease: Leriche syndrome (buttock/thigh claudication, impotence, absent femoral pulses). Infrapopliteal: common in diabetes (tibial vessels). Patterns: single level, multilevel (tandem), diffuse. Reference: Norgren L. J Vasc Surg. 2007 (TASC II).',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Chronic limb-threatening ischemia (CLTI) is defined by:',
'Claudication only', 'Rest pain, non-healing ulcers, or gangrene with objective evidence of arterial disease, present for more than 2 weeks', 'Acute onset', 'Venous disease', 'Trauma',
'B', 'CLTI (formerly critical limb ischemia/CLI): (1) Ischemic rest pain requiring analgesia for greater than 2 weeks, AND/OR (2) Non-healing wound or gangrene, AND (3) Objective arterial disease (ABI less than 0.4, toe pressure less than 30, low TcPO2). Represents end-stage PAD. Prognosis: 1-year amputation rate 25%, 1-year mortality 25%. Requires revascularization (limb salvage) if feasible. Reference: Conte MS. J Vasc Surg. 2019 (GVG Guidelines).',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Acute limb ischemia presents with the 6 Ps:',
'Pallor, Pulselessness, Pain, Paresthesia, Paralysis, and Poikilothermia (cold)', 'Plethora, Palpitations, Pyrexia, Pruritus, Petechiae, Paresis', 'Only pain', 'Only numbness', 'Swelling and redness',
'B', 'Acute limb ischemia 6 Ps: (1) Pain (sudden severe), (2) Pallor (white, then mottled), (3) Pulselessness (absent distal pulses), (4) Paresthesia (sensory loss - early sign), (5) Paralysis (motor loss - late, ominous), (6) Poikilothermia (cold limb). Causes: embolism (cardiac source 80%), thrombosis, trauma, dissection. Diagnosis: clinical, duplex, CTA. Treatment: anticoagulation, revascularization (thrombectomy, bypass, thrombolysis) within 6 hours ideally. Paralysis indicates severe ischemia requiring emergent revascularization or amputation. Reference: Rutherford Classification.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'First-line treatment for intermittent claudication includes:',
'Immediate bypass surgery', 'Supervised exercise therapy, smoking cessation, and cardiovascular risk factor management', 'Amputation', 'Bed rest', 'Anticoagulation only',
'B', 'Claudication management: (1) Exercise: supervised walking program (30-45 min, 3x/week for 12+ weeks) - most effective therapy. (2) Smoking cessation: critical. (3) Risk factor control: statins (all PAD patients), antiplatelet (aspirin or clopidogrel), BP control, diabetes management. (4) Cilostazol: phosphodiesterase inhibitor, improves walking distance (contraindicated in heart failure). Revascularization: reserved for lifestyle-limiting symptoms refractory to conservative therapy. Reference: Gerhard-Herman MD. Circulation. 2017.',
'easy', 'knowledge'),

-- Carotid Artery Disease (36-45)
('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Carotid endarterectomy (CEA) is indicated for symptomatic carotid stenosis of:',
'Any degree', '50-99% stenosis with recent TIA or stroke in the appropriate territory', 'Less than 30%', 'Only complete occlusion', 'Only asymptomatic patients',
'B', 'Symptomatic carotid stenosis: TIA or non-disabling stroke within 6 months in territory of stenotic carotid. CEA indications: (1) 70-99% stenosis: strong benefit (NNT 6 to prevent stroke). (2) 50-69%: moderate benefit (NNT 15), consider patient factors. (3) Less than 50%: no benefit. Timing: ideally within 2 weeks of symptoms (highest stroke risk early). Contraindication: complete occlusion (no benefit). Reference: NASCET. N Engl J Med. 1991.',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'For asymptomatic carotid stenosis, CEA may be considered at:',
'Any stenosis', '60-99% stenosis in patients with acceptable surgical risk and life expectancy', 'Only 30-50%', 'Never indicated', 'Only after stroke',
'B', 'Asymptomatic carotid stenosis: CEA indication controversial. Consider if: (1) 60-99% stenosis (some guidelines say 70-99%), (2) Life expectancy greater than 3-5 years, (3) Perioperative stroke/death risk less than 3%, (4) Patient willing. Benefit smaller than symptomatic (NNT approximately 17 over 5 years). Best medical therapy (BMT) is improving, narrowing benefit gap. Trials: ACAS, ACST. Patient selection crucial. CREST-2 trial ongoing comparing CEA+BMT vs BMT alone. Reference: Halliday A. Lancet. 2010 (ACST).',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Carotid artery stenting (CAS) compared to CEA:',
'Is always preferred', 'May be preferred for high surgical risk patients or hostile neck anatomy, but has higher stroke risk in older patients', 'Has lower stroke risk', 'Never indicated', 'Is the same in all patients',
'B', 'CAS vs CEA: CREST trial showed similar combined outcomes (stroke, MI, death) but: CEA: higher MI risk. CAS: higher stroke risk (especially in patients over 70). CAS may be preferred: hostile neck (prior neck surgery/radiation), surgically inaccessible lesions, recurrent stenosis after CEA, high cardiac risk. CEA preferred: older patients, complex plaque. Both require experienced operators (complication rate less than 6% symptomatic, less than 3% asymptomatic). Reference: Brott TG. N Engl J Med. 2010 (CREST).',
'hard', 'knowledge'),

-- Venous Disease (46-55)
('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Deep vein thrombosis (DVT) is most commonly located in the:',
'Upper extremity', 'Lower extremity veins, especially proximal (popliteal and above)', 'Cerebral veins', 'Portal vein', 'Jugular vein',
'B', 'DVT location: lower extremity most common (90%). Proximal: popliteal, femoral, iliac veins - higher PE risk, require treatment. Distal (calf): below popliteal - lower PE risk, may observe or treat. Upper extremity: less common, often catheter-related (effort thrombosis - Paget-Schroetter). Virchow triad: stasis, endothelial injury, hypercoagulability. Reference: Kearon C. Chest. 2016.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The most common inherited thrombophilia is:',
'Antithrombin deficiency', 'Factor V Leiden (activated protein C resistance)', 'Protein C deficiency', 'Protein S deficiency', 'Prothrombin gene mutation',
'B', 'Factor V Leiden: most common inherited thrombophilia (5% Caucasians). Mechanism: point mutation makes Factor V resistant to inactivation by activated protein C. Heterozygotes: 5-7x increased VTE risk. Homozygotes: 80x increased risk. Testing: APC resistance assay, genetic testing. Other common: prothrombin G20210A mutation (2-3% Caucasians). Rare but severe: antithrombin, protein C, protein S deficiency. Testing indicated: unprovoked VTE, young age, recurrent VTE, family history. Reference: Rosendaal FR. Lancet. 1999.',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Treatment of acute proximal DVT includes:',
'Observation only', 'Anticoagulation with LMWH, DOACs, or warfarin, with early ambulation', 'Immediate surgery always', 'Aspirin only', 'Bed rest for 2 weeks',
'B', 'DVT treatment: (1) Anticoagulation: DOACs (rivaroxaban, apixaban) preferred for most, OR LMWH bridging to warfarin. Duration: 3 months minimum, extended for unprovoked or recurrent. (2) Early ambulation: encouraged (no increased PE risk). Bed rest not required. (3) Compression stockings: uncertain benefit for PTS prevention (recent data). (4) Thrombolysis: consider for massive iliofemoral DVT, limb-threatening. (5) IVC filter: contraindication to anticoagulation, recurrent PE on anticoagulation. Reference: Kearon C. Chest. 2016.',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Chronic venous insufficiency most commonly results from:',
'Arterial disease', 'Deep vein thrombosis causing valvular incompetence (post-thrombotic syndrome)', 'Lymphatic obstruction', 'Heart failure', 'Renal failure',
'B', 'Chronic venous insufficiency (CVI): caused by venous reflux (valvular incompetence) or obstruction. Etiology: (1) Primary: idiopathic valve incompetence. (2) Secondary: post-thrombotic (DVT damages valves), most common cause. Features: edema, skin changes (hemosiderin, lipodermatosclerosis), varicose veins, venous ulcers (medial malleolus). CEAP classification: Clinical, Etiology, Anatomy, Pathophysiology. Treatment: compression therapy, wound care, superficial vein ablation if reflux. Reference: Eberhardt RT. Circulation. 2014.',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Venous ulcers are typically located at:',
'Toes', 'Medial malleolus (gaiter area) with irregular borders and shallow base', 'Pressure points', 'Lateral malleolus', 'Plantar foot',
'B', 'Venous ulcer characteristics: (1) Location: medial malleolus (gaiter area), (2) Appearance: irregular borders, shallow, moderate exudate, granulating base, (3) Associated findings: edema, varicosities, skin changes (hemosiderin staining, lipodermatosclerosis). Vs arterial ulcers: lateral/dorsal foot, punched out, dry base, painful, absent pulses. Treatment: compression therapy (essential - 30-40 mmHg), wound care, treat superficial reflux, pentoxifylline adjunct. Reference: ODeaMeara S. Cochrane. 2012.',
'easy', 'knowledge'),

-- Aortic Dissection (56-60)
('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Stanford Type A aortic dissection involves:',
'Descending aorta only', 'The ascending aorta regardless of where the tear originated (surgical emergency)', 'Abdominal aorta only', 'Iliac arteries', 'Only the arch',
'B', 'Stanford classification: Type A: involves ascending aorta (proximal to brachiocephalic) regardless of origin - SURGICAL EMERGENCY. Type B: involves only descending aorta (distal to left subclavian) - usually medical management. DeBakey: Type I (ascending + descending), Type II (ascending only), Type III (descending only). Type A complications: aortic rupture, tamponade, aortic regurgitation, coronary occlusion, stroke. Type B: uncomplicated = medical, complicated (malperfusion, rupture) = intervention. Reference: Nienaber CA. Circulation. 2003.',
'medium', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'The hallmark symptom of acute aortic dissection is:',
'Gradual onset chest pain', 'Sudden severe tearing or ripping chest or back pain with maximal intensity at onset', 'Shortness of breath only', 'Palpitations', 'Leg swelling',
'B', 'Aortic dissection presentation: (1) Pain: sudden onset, severe, tearing/ripping quality, maximal at onset (vs MI which crescendos), chest (Type A) or back (Type B), migratory. (2) Hypertension (or hypotension if rupture/tamponade). (3) Pulse deficits (branch vessel involvement). (4) Aortic regurgitation murmur (Type A). (5) Neurological deficits. Risk factors: hypertension, Marfan syndrome, bicuspid aortic valve, cocaine. Diagnosis: CTA (first-line), TEE. Reference: Hagan PG. JAMA. 2000 (IRAD).',
'easy', 'knowledge'),

('c0000058-0000-0000-0000-000000000058', 'a0000003-0000-0000-0000-000000000003',
'Initial medical management of aortic dissection includes:',
'Inotropes to increase cardiac output', 'Heart rate and blood pressure control with beta-blockers as first-line (target HR less than 60, SBP 100-120)', 'Thrombolytics', 'Antiplatelet agents', 'Immediate surgery for all cases',
'B', 'Aortic dissection medical therapy: Goal: reduce aortic wall stress (dP/dt). (1) Beta-blockers first: IV esmolol, labetalol, metoprolol - reduce HR (target less than 60) and contractility. (2) Then add vasodilators if needed: nitroprusside, nicardipine - target SBP 100-120 mmHg. Never give vasodilators before beta-blockade (reflex tachycardia worsens dissection). Pain control: opioids. All Type A: urgent surgery. Type B uncomplicated: medical. Type B complicated: intervention (TEVAR). Reference: Erbel R. Eur Heart J. 2014.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 43 (Vascular Surgery): 60 questions inserted' as status;
